Hip Replacement Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Total hip arthroplasty (THA), commonly called hip replacement surgery, is one of the most frequently performed and cost-effective elective orthopaedic procedures worldwide. More than one million THA procedures are performed annually across the United States, United Kingdom, Germany, Australia, and India combined, with global volumes continuing to rise as populations age and as younger patients seek hip replacement for end-stage arthritis after conservative management has failed.

The procedure involves removing damaged articular cartilage and underlying bone from the femoral head and acetabulum, then implanting an artificial joint — comprising a metal acetabular shell (cup), a liner (bearing surface), a femoral stem, and a modular femoral head — to recreate a smooth, pain-free ball-and-socket joint. Modern THA implants and surgical techniques produce predictable pain relief, restoration of function, and durable implant survival rates that rank among the best outcomes of any elective surgical procedure in medicine.

The surgical approach — how the hip joint is accessed — influences muscle disruption, dislocation risk, rehabilitation pace, and technical difficulty. Implant fixation method — cemented, cementless press-fit, or hybrid — determines how the prosthesis integrates with the patient's bone and has significant implications for implant longevity and revision complexity. Bearing surface selection — the materials comprising the articulating cup liner and femoral head — determines wear characteristics, wear debris inflammatory response, and long-term revision risk.

National joint replacement registries — the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), the UK National Joint Registry (NJR), the Swedish Hip Arthroplasty Register (SHAR), and the American Joint Replacement Registry (AJRR) — collect outcomes data on millions of THA procedures, providing the highest-quality real-world evidence on implant survival, revision rates, and patient outcomes to guide implant selection and surgical decision-making.

THA is indicated when hip joint destruction produces severe pain and functional disability that significantly impairs quality of life and cannot be adequately managed by non-operative means. The following conditions represent the principal diagnoses leading to THA.

Primary Osteoarthritis (OA): The dominant indication for THA, accounting for approximately 80–85% of all primary hip replacements in the US and Australia. OA results from progressive articular cartilage degradation, subchondral bone sclerosis and cyst formation, osteophyte development, and synovial inflammation. End-stage OA is characterized by complete loss of joint space on weight-bearing radiographs, bone-on-bone articulation, severe pain at rest and with minimal activity, and significant limitation in walking distance and activities of daily living.

Avascular Necrosis (AVN) of the Femoral Head: Also known as osteonecrosis, AVN results from disrupted vascular supply to the femoral head, leading to bone death, structural collapse, and secondary OA. Common causes include corticosteroid use, excessive alcohol consumption, sickle cell disease, prior femoral neck fracture, Gaucher disease, and radiation exposure. Ficat stage III and IV disease (collapsed femoral head) typically requires THA rather than femoral head-preserving procedures.

Rheumatoid Arthritis and Inflammatory Arthropathies: Inflammatory joint diseases — rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus — can destroy the hip joint through pannus formation and synovial inflammation. THA in inflammatory arthropathy patients is complicated by bone stock deficiency, protrusio acetabuli deformity, and immunosuppressive medication management perioperatively. Modern biologic therapies have reduced hip destruction rates in RA, but THA remains the definitive treatment for established joint failure.

Post-Traumatic Arthritis: Prior fractures of the acetabulum, femoral neck, or femoral head can result in malunion, cartilage injury, and progressive post-traumatic OA requiring THA. Conversion THA after failed hip fracture internal fixation (dynamic hip screw, cannulated screws) is technically more challenging than primary THA due to retained hardware, altered anatomy, and reduced bone quality.

Femoral Neck Fractures: Displaced femoral neck fractures (Garden types III and IV) in elderly patients are increasingly treated with hemiarthroplasty (femoral stem + head without acetabular cup) or THA rather than internal fixation, given the high failure rate of fixation in osteoporotic bone and the dislocation risk of surgical management in cognitively impaired patients. THA is preferred over hemiarthroplasty for physiologically active older patients (typically under 75 years) due to superior long-term functional outcomes and avoidance of acetabular erosion.

Failed Prior Hip Surgery: Prior hip arthroscopy with progressive arthritis, failed periacetabular osteotomy, failed hip resurfacing, and prior failed hemiarthroplasty are all indications for conversion to primary or revision THA.

Patient selection for THA balances the severity of hip disability against surgical risk and realistic expectations regarding outcomes. The following criteria guide candidacy assessment.

Clinical Indications: Severe hip pain limiting walking to less than 15–20 minutes or causing significant nocturnal pain; inability to perform activities of daily living including dressing, bathing, and climbing stairs without significant hip-related difficulty; objective radiographic evidence of end-stage joint disease; and failure of an adequate trial of non-operative management including weight loss, physiotherapy, NSAIDs, activity modification, and intra-articular corticosteroid or hyaluronic acid injection.

Radiographic Criteria: Plain AP pelvis and lateral hip radiographs showing Tonnis grade 3 or Kellgren-Lawrence grade 3–4 osteoarthritis with significant joint space narrowing (<2 mm), subchondral sclerosis and cyst formation, osteophyte formation, and (in advanced cases) bone-on-bone contact. Templating — overlaying implant templates on preoperative radiographs — guides implant size selection, leg length planning, and offset correction.

Medical Optimization: Patients require medical optimization before elective THA. Cardiovascular risk stratification (ECG, echocardiogram in selected patients) following ACC/AHA guidelines is standard. HbA1c below 8% is targeted for diabetic patients; obesity (BMI >40) substantially increases infection, dislocation, and wound complication rates and weight loss programs are often recommended before surgery. Active infection anywhere in the body must be eradicated before elective joint implantation. Anticoagulation bridging plans must be established with the managing physician. Anemia (hemoglobin below 120 g/L in women, below 130 g/L in men) should be corrected preoperatively to reduce allogenic blood transfusion rates.

Age Considerations: THA is performed across a wide age range — from patients in their late 30s with AVN or inflammatory arthropathy to patients in their 90s with displaced femoral neck fractures. Younger patients (<60 years) present unique challenges: higher functional demands accelerate implant wear, longer life expectancy increases the probability of requiring revision surgery, and cumulative lifetime radiation from multiple follow-up radiographs is a consideration. Bearing surface selection, fixation method, and implant design are optimized for age-specific needs.

THA technique encompasses three interrelated decisions: surgical approach, implant fixation method, and bearing surface selection. Each has distinct trade-offs that must be matched to the individual patient.

Surgical Approaches:

• Posterolateral approach: The most commonly used approach worldwide. The hip is accessed through the posterior capsule with division of the short external rotator tendons (piriformis, obturator internus, gemelli). Advantages include excellent visualization, applicability across all body habitus, and lower risk of abductor damage. Historical dislocation rate of 3–5% has been reduced to approximately 0.5–2% with posterior capsule repair. The main approach at high-volume centers in the US, Australia, and UK.
• Anterolateral (Hardinge / direct lateral) approach: Accesses the hip through the anterior portion of the gluteus medius muscle, partially detaching it from the greater trochanter. Lower dislocation rate than posterior approach due to posterior capsule preservation. Drawbacks include abductor weakness (Trendelenburg gait) in 5–15% of patients from gluteus medius damage, and trochanteric heterotopic ossification risk.
• Direct Anterior Approach (DAA / Hueter approach): The hip is accessed through the internervous interval between the tensor fasciae latae (TFL) and sartorius muscles, with no muscle detachment. Benefits include earlier functional recovery, lower dislocation rate, supine positioning facilitating intraoperative fluoroscopy for limb length assessment, and possible early return to driving. Drawbacks include a steeper learning curve, higher rates of lateral femoral cutaneous nerve injury, and limited utility in obese patients or revision surgery. Specialized traction tables are used.
• SuperPath and SPAIRE approaches: Tissue-sparing modifications of the posterolateral approach that preserve the piriformis and posterior capsule more completely, aiming to reduce dislocation risk and enable more rapid functional recovery. Gaining adoption at specialized centers.

Implant Fixation Methods:

• Cementless (press-fit) fixation: The dominant fixation method in patients under 65–70 years. Porous-coated titanium alloy implants (TiO2 or hydroxyapatite surface treatment) are press-fit into prepared bony beds; bone ingrowth into the porous surface over 6–12 weeks achieves biological fixation. AOANJRR data at 10 years shows cementless cup revision rates of approximately 3–5%. Requires adequate bone stock and cortical contact.
• Cemented fixation: Polymethylmethacrylate (PMMA) bone cement interdigitates with cancellous bone to achieve immediate rigid fixation. Preferred in patients over 75 years with osteoporotic bone, metabolic bone disease, or poor bone quality where press-fit is unreliable. The cemented Exeter stem (Stryker) has one of the best long-term registry records in orthopaedic history — 95%+ survival at 20 years. NJR data shows cemented stems have slightly lower long-term revision rates than cementless in elderly patients.
• Hybrid fixation: Combines a cementless acetabular cup (biological fixation is superior for the socket) with a cemented femoral stem (more reliable in compromised femoral bone). Widely used in the UK and Scandinavia. AOANJRR data supports hybrid as a reliable fixation construct in patients over 65.

Bearing Surface Selection:

• Ceramic-on-highly-crosslinked-polyethylene (CoXLPE): The most commonly implanted bearing surface combination globally. Alumina or alumina-zirconia composite ceramic heads paired with highly-crosslinked polyethylene (HXLPE) liners produce volumetric wear rates of less than 0.05 mm per year — a 90% reduction compared to conventional polyethylene. NJR data consistently demonstrates the lowest revision rates for this combination in patients across all age groups. Fracture risk of modern ceramics is extremely low (<0.01%).
• Ceramic-on-ceramic (CoC): The hardest, most scratch-resistant surface. Wear rates are nearly undetectable (<0.001 mm/year). Indicated for young, very active patients. Drawbacks include squeaking (audible in 0.5–2% of patients, related to fluid film disruption) and catastrophic fracture risk (0.01–0.02%). Third-generation alumina ceramics (BIOLOX delta, BIOLOX forte) have substantially reduced fracture incidence.
• Metal-on-metal (MoM) — historical context: Large-head MoM THA was extensively used 2000–2012 based on theoretical advantages of stability and low dislocation rates with large femoral heads (36 mm+). Subsequent surveillance revealed unacceptably high rates of adverse reactions to metal debris (ARMD) — pseudotumors, tissue necrosis, and pain — due to corrosion at the head-neck taper junction and metal-on-metal articulation generating cobalt-chromium nanoparticles. The UK MHRA issued safety alerts in 2010 and 2012 mandating annual blood metal ion monitoring and MARS MRI for all patients with large-head MoM hips. Most MoM THA implants have since been withdrawn from market; this bearing surface is no longer recommended for primary THA.
• Conventional polyethylene (historical): Prior to crosslinking, polyethylene (UHMWPE) produced osteolysis-inducing wear debris that drove aseptic loosening — the dominant failure mode of THA before 1995. Modern HXLPE has largely eliminated this problem.

Total hip arthroplasty is one of the most reliably successful elective surgical procedures in all of medicine. Patient-reported outcomes and registry survival data support THA as a highly cost-effective intervention with durable benefits.

Pain Relief: Approximately 90–95% of patients achieve substantial or complete relief of the preoperative hip pain that prompted surgery. VAS pain scores typically decrease from 7–9 out of 10 preoperatively to 1–2 out of 10 at 6 months postoperatively. The rapidity of pain relief — often dramatic within the first 2–4 weeks — is one of the most gratifying features of THA from a patient perspective.

Functional Restoration: Patient-reported functional outcome scores — Oxford Hip Score (OHS), WOMAC, Harris Hip Score (HHS), and HOOS — demonstrate significant improvements in walking distance, stair climbing, sleep quality, social participation, and activities of daily living. Most patients regain the ability to walk unlimited distances on level ground, travel, and participate in low-impact recreational activities within 3–6 months of surgery.

Implant Survival: Registry data from the AOANJRR, NJR, and SHAR represent the largest and most reliable sources of THA survival data. As of 2023 annual reports: the cumulative revision rate for primary THA at 10 years is approximately 5–8% for most modern implant-fixation-bearing surface combinations; cemented Exeter stems show 95%+ survival at 15–20 years in appropriately matched patients; cementless cementless constructs with CoXLPE bearings demonstrate 92–95% implant survival at 15 years. These registry survival rates translate to the commonly cited patient-facing statistic that 9 of 10 patients will not need revision surgery within 10 years.

Quality of Life and Cost-Effectiveness: THA consistently ranks among the highest QALY (quality-adjusted life year) gain per dollar spent of any elective surgery. UK NICE economic analyses confirm THA as highly cost-effective below standard willingness-to-pay thresholds. The reduction in analgesic consumption, physical therapy utilization, and healthcare contacts following successful THA contributes substantially to long-term cost savings offsetting the surgical investment.

Enhanced Recovery Protocols (ERAS): Modern ERAS protocols — multimodal analgesia (periarticular infiltration, spinal anesthesia with intrathecal opioid, peripheral nerve blocks), same-day ambulation, minimized hospital stay (often 1 day or outpatient in selected patients), and early physical therapy — have reduced hospital length of stay from 5–7 days (historical) to 1–2 days without increasing complication or readmission rates. This represents a major advance in patient experience and healthcare efficiency.

THA carries risks that are well-characterized from large registry datasets and randomized trial data. Informed consent must include discussion of the following complication categories.

Venous Thromboembolism (VTE): Deep vein thrombosis (DVT) was historically the most common complication of THA, with symptomatic DVT rates of 2–5% and pulmonary embolism (PE) rates of 0.5–2% without prophylaxis. Modern chemoprophylaxis — low-molecular-weight heparin (LMWH), direct oral anticoagulants (rivaroxaban, apixaban), aspirin, or fondaparinux continued for 14–35 days postoperatively — combined with mechanical prophylaxis (compression stockings, pneumatic compression devices) reduces symptomatic VTE rates to approximately 0.3–1%. Fatal PE occurs in approximately 0.1–0.2% of primary THA patients on contemporary protocols.

Periprosthetic Joint Infection (PJI): The most feared complication of THA, with a reported incidence of 0.5–2% for primary THA. PJI may be acute (within 3 months, typically caused by Staphylococcus aureus or gram-negative organisms from wound contamination) or chronic (low-grade, caused by coagulase-negative staphylococci or polymicrobial flora). Treatment requires surgical debridement with component exchange or two-stage revision with cement spacer, plus prolonged IV and oral antibiotics. Risk factors include obesity (BMI >40), diabetes with poor glycemic control, immunosuppression, prior PJI, malnutrition, and smoking. CDC/AAOS perioperative prophylaxis protocols with pre-incision IV cefazolin and chlorhexidine skin preparation reduce PJI risk.

Dislocation: Prosthetic hip dislocation rates in primary THA range from 0.5–3% with modern techniques and implant designs. Posterior dislocation is most common, presenting as severe pain, internal rotation deformity, and inability to bear weight. Risk factors include posterior approach (without capsule repair), large acetabular inclination or anteversion errors, neurological conditions reducing muscle tone, and cognitive impairment. Modern large femoral heads (36–40 mm) and dual-mobility cup designs have substantially reduced dislocation rates. First-time dislocation is managed with closed reduction under sedation; recurrent dislocations require revision surgery.

Leg Length Discrepancy (LLD): Inequality in limb lengths after THA is a frequent source of patient dissatisfaction. Discrepancies of less than 10 mm are usually asymptomatic and self-correct with adaptation. Discrepancies of 10–20 mm may cause back pain, gait abnormality, or the subjective sense of asymmetry. Careful preoperative templating, intraoperative measurement, and use of modular implant systems minimize LLD. True LLD greater than 20 mm post-THA is increasingly an indication for revision or shoe-lift correction.

Nerve Injury: Sciatic nerve injury occurs in approximately 0.5–1% of primary THA cases, more commonly with posterior approach, hip dysplasia revision, and excessive limb lengthening. Most are neuropraxias that recover fully or partially within 6–18 months. Femoral nerve injury from retractor placement is more common in anterior approaches. Superior gluteal nerve injury can cause abductor weakness with anterolateral approaches.

Periprosthetic Fracture: Intraoperative or postoperative fractures around the implant occur in 0.1–1% of primary THA; rates rise to 3–5% in revision THA. Vancouver classification guides management — undisplaced fractures (type A1, B1) are managed with protected weight-bearing; displaced or stem-unstable fractures (B2, B3, C) require open reduction and internal fixation or revision to longer stem prostheses.

Aseptic Loosening: Progressive loss of implant-bone bond over years to decades, without infection, results in osteolysis, pain with weight-bearing, and ultimately implant subsidence or migration. Modern HXLPE liners have substantially reduced wear-particle-driven osteolysis. Cemented stems may develop cement mantle cracking. Aseptic loosening is the dominant long-term revision indication, accounting for approximately 30% of revisions in registry data.

Postoperative management of THA patients follows structured enhanced recovery protocols that prioritize early mobilization, pain control, and complication surveillance.

Inpatient Phase (Day 0–2): Most patients mobilize — stand and take initial steps — within 4–6 hours of surgery under the guidance of a physiotherapist. Early mobilization reduces DVT risk and deconditioning. IV fluids are minimized once oral intake resumes. Multimodal analgesia combines regular paracetamol (acetaminophen), NSAIDs (if not contraindicated), periarticular or adductor canal local anesthetic infiltration, and oral opioids as needed. Dislocation precautions (avoid hip flexion >90 degrees, internal rotation, and adduction past midline) are taught for posterior approach; anterior approach patients may have fewer restrictions. A physiotherapist provides instruction in crutch/walking frame use and home exercise program. Most primary THA patients are discharged to home (not to inpatient rehabilitation) on postoperative day 1 in high-volume enhanced recovery programs.

Early Home Recovery (Weeks 1–6): Wound check at 10–14 days to assess healing and remove clips/sutures. Anticoagulation (rivaroxaban, apixaban, LMWH, or aspirin) continues for 14–35 days. Physical therapy visits 2–3 times per week for gait training, range-of-motion, strengthening, and stair training. Driving is typically permitted at 6 weeks after right THA (earlier for left THA automatic transmission vehicles); this timeline is surgeon-dependent. Swelling, bruising, and mild aching pain are normal. Low-grade fever up to 38.5 degrees Celsius for the first 2–3 days is common; fever beyond this or wound discharge requires urgent assessment to exclude infection.

Outpatient Follow-Up: Clinical and radiographic review at 6 weeks, 3 months, and 12 months in the first year, then every 1–2 years thereafter. Radiographs assess implant position, leg length equality, bone remodeling, and early signs of loosening or osteolysis. Patient-reported outcomes (Oxford Hip Score, HOOS) are collected in many centers and nationally in NJR-contributing institutions. Patients with metal-on-metal implants require annual cobalt and chromium ion blood level monitoring per MHRA guidance, and MARS MRI if ions exceed thresholds or symptoms suggest ARMD.

Long-Term Surveillance: Patients are counseled to report immediately any sudden pain, inability to weight-bear, reduced range of motion, or wound changes that may suggest dislocation, fracture, or late infection. Regular low-dose AP pelvis radiographs at 5–7 year intervals allow early detection of asymptomatic osteolysis, enabling intervention before major bone loss requires complex reconstruction.

The cost of primary THA varies dramatically between countries and care settings, making it a major driver of medical tourism for patients without insurance coverage or facing long NHS/public system waiting lists.

United States: Hospital charges for primary THA average USD 30,000–80,000 depending on hospital type, metropolitan area, and insurance negotiated rates. Implant costs alone contribute USD 5,000–15,000 per case. Surgeon and anesthesiology professional fees add USD 3,000–8,000. Total out-of-pocket costs for uninsured patients routinely exceed USD 40,000–80,000. Medicare pays approximately USD 13,000–18,000 as a global payment (bundled payment model under BPCI/CJR programs). Commercial insurance patients typically face deductibles of USD 3,000–10,000 after which coverage at 80–100% applies.

United Kingdom: NHS primary THA is free at the point of service, but wait times of 12–24 months are increasingly common post-pandemic. Private THA in the UK costs GBP 10,000–18,000 all-inclusive (USD 12,000–22,000 at current rates), using the same implant systems as NHS with faster access and private room amenity.

India: India has become the leading medical tourism destination for THA. JCI-accredited hospitals in Mumbai (Kokilaben Dhirubhai Ambani Hospital, Hinduja Hospital), Delhi (Max Healthcare, Fortis), Chennai (Apollo Hospitals, MIOT International), and Hyderabad (Yashoda) perform THA using imported US and European implants (Stryker, Zimmer Biomet, DePuy Synthes, Smith+Nephew) for an all-inclusive cost of USD 6,000–12,000. Indian-manufactured implants reduce cost to USD 4,000–7,000 without significantly compromising quality at established centers. Surgeon training at top Indian hospitals frequently includes fellowship in UK, US, or Australia.

Thailand, Malaysia, Singapore: Bumrungrad International Hospital (Bangkok), BNH Hospital, Prince Court Medical Centre (Kuala Lumpur), and Gleneagles Singapore offer THA for USD 10,000–20,000 all-inclusive with internationally trained surgeons, imported implants, and JCI accreditation. These destinations appeal to patients from Southeast Asia, Middle East, and Australia seeking shorter wait times and premium amenities.

Implant Cost Variation: Bearing surface and implant generation significantly affect implant procurement cost. Ceramic heads are more expensive than cobalt-chromium heads (approximately USD 300–800 additional). Highly crosslinked polyethylene liners are more expensive than conventional UHMWPE. Custom-fit implants (computer-assisted planning, patient-specific instrumentation) add USD 1,000–3,000 per case. These cost differences are generally not passed on to insured patients but affect medical tourism pricing.

THA is not the only management option for end-stage hip disease, and several alternatives or adjuncts merit consideration depending on patient age, disease severity, and specific pathology.

Conservative Management: For mild-to-moderate hip OA, a structured program of weight loss (target BMI <30), low-impact aerobic exercise, physiotherapy, and NSAIDs can maintain acceptable function for years and delay the need for surgery. ACR/EULAR guidelines recommend walking, aquatic exercise, and hip strengthening as first-line management for hip OA. Intra-articular corticosteroid injections provide short-term (6–12 week) pain relief. Hyaluronic acid (viscosupplementation) injections have inconsistent evidence for hip OA compared to knee OA.

Hip Arthroscopy: In younger patients with FAI-related secondary OA (Tonnis grade 0–1), hip arthroscopy with cam/pincer correction and labral repair can interrupt the progression to severe OA and delay or avoid hip replacement. As noted above, advanced OA (Tonnis grade 2–3) is a contraindication to arthroscopy.

Hip Resurfacing: Birmingham Hip Resurfacing (BHR) and similar devices preserve the femoral neck by capping the femoral head with a metal surface rather than replacing the femoral stem. Discussed in detail in the dedicated hip resurfacing guide. Resurfacing is appropriate only for highly selected patients (young active males, large femoral heads, excellent bone stock, no femoral neck deformity or osteonecrosis) — in all others, conventional THA produces superior outcomes.

Osteotomy: Femoral or acetabular osteotomies can redistribute load in younger patients with dysplasia or post-traumatic malalignment, delaying OA progression. Periacetabular osteotomy (PAO) for hip dysplasia is effective in patients under 40 with preserved articular cartilage. Intertrochanteric valgus or varus osteotomy has largely been replaced by THA and hip arthroscopy in contemporary practice.

Hemiarthroplasty vs THA for Femoral Neck Fractures: In displaced femoral neck fractures in elderly patients, hemiarthroplasty (replacing only the femoral component without an acetabular cup) provides faster surgery, lower dislocation risk, and adequate early function in lower-demand patients. The HEALTH trial (NEJM, 2019) demonstrated that THA and hemiarthroplasty had similar 24-month function in patients over 50 years with displaced femoral neck fractures, but THA patients had lower rates of reoperation. Current AAOS guidance recommends THA for active patients with displaced femoral neck fractures under 70–75 years, and either hemiarthroplasty or THA for those over 75 based on functional demand and operative risk.